Verismo's KIR-CAR Nears Debut with $28M for Solid Tumor Fight

PHILADELPHIA, PA – April 15, 2026 – Verismo Therapeutics, a clinical-stage biotechnology company, has secured a $28 million investment from its parent company, HLB Innovation. The substantial funding arrives at a pivotal moment, just days before the company is scheduled to present the first-ever clinical data on its novel KIR-CAR platform at a prestigious oncology conference, potentially heralding a new chapter in the fight against hard-to-treat cancers.

The investment is earmarked to accelerate the development of Verismo’s two lead candidates: SynKIR™-110, which targets advanced solid tumors expressing mesothelin, and SynKIR™-310, for patients with relapsed or refractory B cell non-Hodgkin lymphomas. Both therapies are currently in Phase 1 clinical trials.

A Critical Juncture for a Next-Generation Therapy

The timing of the investment underscores the high stakes and anticipation surrounding Verismo's work. On April 20, the company will take the stage at the American Association for Cancer Research (AACR) Annual Meeting's Late-Breaking Clinical Trials plenary session—a forum reserved for research with the potential to significantly alter clinical practice. This presentation will mark the first public disclosure of clinical safety and efficacy data for a KIR-CAR candidate, specifically from the STAR-101 trial of SynKIR™-110.

"This investment from HLB Innovation comes at a pivotal moment for Verismo and for the KIR-CAR platform," said Bryan Kim, CEO and Co-Founder of Verismo Therapeutics, in a statement. "This funding ensures we have the resources to fully capitalize on that momentum — advancing our solid tumor and blood cancer programs toward the data readouts that will define the potential for multi-chain KIR-CAR cell therapy to provide durable results over current single-chain CAR Ts."

Selection for the AACR plenary session is a significant validation in itself, signaling to the oncology community that the initial findings are of considerable interest. It places Verismo's technology under a bright spotlight, with researchers, clinicians, and investors watching closely for a first glimpse into its performance in human subjects.

The Science Behind KIR-CAR: A New Weapon Against Solid Tumors?

Verismo's entire approach is built on addressing a fundamental challenge that has hampered one of modern medicine's most promising cancer treatments: CAR T-cell therapy. While conventional single-chain CAR T therapies have shown remarkable success in treating certain blood cancers, their effectiveness against solid tumors has been severely limited.

The primary culprit is a phenomenon known as T-cell exhaustion. The engineered T-cells, upon entering the hostile microenvironment of a solid tumor, are subjected to constant signaling that causes them to tire out and lose their cancer-fighting ability, leading to short-lived responses.

Verismo's KIR-CAR platform was designed from the ground up to overcome this obstacle. Unlike conventional CARs, it employs a multi-chain structure that mimics the natural signaling of Killer Immunoglobulin-like Receptors (KIR) found on the body's own Natural Killer (NK) cells. By pairing a modified KIR receptor with a signaling partner called DAP12, the platform effectively decouples target binding from T-cell activation. This novel design is intended to prevent the constant background signaling that leads to exhaustion, allowing the engineered T-cells to persist and maintain their function for longer periods within the tumor.

This improved functional persistence is the key advantage Verismo hopes to demonstrate. If the KIR-CAR T-cells can remain active and durable, they could deliver more profound and lasting anti-tumor effects, particularly against the challenging solid tumors that make up the vast majority of cancer cases. As the sole developer of this unique KIR-CAR platform, Verismo holds a distinct position in the competitive cell therapy landscape.

HLB's Strategic Bet and the Crowded Field

The $28 million cash injection is more than just financial fuel; it is a calculated strategic move by South Korean life sciences conglomerate HLB Innovation. The investment deepens its control over Verismo, which became a subsidiary in late 2024, and aligns with HLB Group's broader strategy of acquiring and aggressively funding promising biotech assets with the potential for global impact. This move provides Verismo with a stable runway to navigate the costly and lengthy process of clinical development while positioning HLB to capitalize on any future success through licensing deals or market entry.

The investment also places Verismo on firmer footing within the fiercely competitive cell therapy market. While industry giants like Novartis, Kite Pharma, and Bristol Myers Squibb have established blockbuster CAR T products for hematologic malignancies, the race to conquer solid tumors is still wide open. Success in this area would represent a monumental breakthrough and unlock a market vastly larger than that for blood cancers.

Verismo's upcoming presentations at AACR will showcase the breadth of its platform beyond the headline plenary session. The company will also present preclinical data suggesting SynKIR™-310 outperforms other CAR T models in B cell lymphoma and additional late-breaking findings on a KIR-CAR approach for glioblastoma, further demonstrating the platform's versatility.

Hope on the Horizon for Patients

Beyond the science and financials, the true significance of Verismo's work lies in its potential to help patients with grim prognoses. Advanced mesothelin-expressing solid tumors—including aggressive cancers like mesothelioma, pancreatic cancer, and ovarian cancer—are notoriously difficult to treat, with high mortality rates and limited therapeutic options once they have spread.

For these patients, and for those with B cell lymphomas who have relapsed after or are refractory to existing treatments, the need for new, more effective therapies is urgent. The upcoming data from the STAR-101 trial represents a tangible step toward a potential new solution. While a Phase 1 trial's primary goal is to establish safety and determine the right dose, any signals of clinical activity, such as tumor shrinkage or disease stabilization, would be a powerful validation of the KIR-CAR platform's promise.

The oncology world will be watching on April 20th. The initial results from this first-in-human study could provide the first concrete evidence that the KIR-CAR platform's elegant design translates into meaningful clinical benefit, offering a new ray of hope for patients and potentially reshaping the future of cellular immunotherapy.